SYS6077
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 15, 2026
A Clinical Trial to Evaluate the Safety and Tolerability of SYS6077 Injection in Participants With Advanced Malignant Tumor
(clinicaltrials.gov)
- P1 | N=110 | Not yet recruiting | Sponsor: Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1